Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab
Introduction: Ocrelizumab is a recombinant humanized anti-CD20 monoclonal antibody used to treat multiple sclerosis. Late-onset neutropenia, absolute neutrophil count <1.5 × 109/L that develops >4 weeks after last drug administration, is a known adverse event associated with...
| Published in: | Case Reports in Neurology |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-03-01
|
| Online Access: | https://karger.com/article/doi/10.1159/000544749 |